<DOC>
	<DOC>NCT02603055</DOC>
	<brief_summary>Hepatitis E is characteristic by sporadic and local epidemic around the world, and mainly infects adults aged 15 to 40 years old, resulting in the infection rate ranged from 1% to 15%. The investigational hepatitis E vaccine is a recombinant aluminium-adjuvant hepatitis E vaccine. This is a single center, randomized, blinding, parallel-controlled phase Ib clinical trial. This study will determine the safety and immunogenicity of the investigational recombinant hepatitis E vaccine in healthy adults between 16 and 65 years.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged between 16 and 65 years with normal intelligence. Negative in antibody against hepatitis E test. No plan to go out for a long time within 9 months. Able to understand the content of informed consent and willing to sign the informed consent General good health as established by medical history and physical examination. Able and willing to complete all the secluded study process during the whole study followup period. No history of hepatitis B, hepatitis C and hepatitis E(Patients diagnosed as hepatitis B, hepatitis C and hepatitis E by town or above) Axillary temperature ≤37.0°C on the day of enrollment Woman who is pregnant, breastfeeding or planning to be pregnant during the study period Allergic history of any vaccination or drugs, or allergic to any ingredient of the Hepatitis E vaccine History of serious adverse reactions after vaccination, such as allergies, urticaria, breathing difficulties, angioneurotic oedema or abdominal pain Autoimmune disease or immunodeficiency Asthma that was unstable and need emergency treatment, hospitalization, oral or intravenous corticosteroid within two years Type I or II diabetes, not including gestational diabetes History of thyroidectomy, or need treatment for thyroid disease in the past 12 months History of serious angioneurotic edema in the past 3 years, or need treatment for it in the past 2 years Severe hypertension, with the blood pressure still more than 150/100 mmHg after drug maintenance treatment Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or coagulation disorders diagnosed by the doctor. Patients who are active or not have a definite cure of malignant tumors, or who may recur in the study period. Epilepsy, not including alcohol epilepsy in the first 3 years abstinence or simple epilepsy without the need of treatment in the past 3 years Asplenia or functional asplenia, or asplenia and splenectomy under any circumstances Guillain Barre Syndrome Prior administration of immunodepressant, cytotoxic or corticosteroids (not including corticosteroid therapy for allergic rhinitis and acute non concurrent dermatitis )treatment in last 6 months Prior administration of immune globulin in last 3 months Prior administration of other research medicines in last 1 month Prior administration of attenuated vaccine in last 1 month Prior administration of subunit or inactivated vaccine in last 14 days, such as pneumococcal Vaccine Current antituberculosis prophylaxis or therapy Fever (axillary temperature 38.0℃) in 3 days before vaccination or any acute disease, systemic application of antibiotics or antiviral therapy in the past five days Unable to comply with the study requirements due to the psychological situation, a past or present history of mental disease, twostage affective psychosis which were not well controlled in the past two years; mental disease need medical treatment, and have suicidal tendency over the past five years Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>Hepatitis E</keyword>
</DOC>